Cargando…

Diagnostic Challenges and Treatment Options for Cutaneous T Cell Pseudolymphoma: A Case Study with Rituximab Treatment

Patient: Female, 46-year-old Final Diagnosis: Cutaneous T cell pseudolymphoma Symptoms: Enlarged cervical lymph nodes Medication: — Clinical Procedure: — Specialty: Hematology OBJECTIVE: Rare disease BACKGROUND: Pseudolymphoma is a rare disorder that can mimic lymphoma both clinically and histologic...

Descripción completa

Detalles Bibliográficos
Autores principales: Balode, Dārta, Belajeva, Ludmila, Ruesseler, Vanessa, Quaas, Alexander, Lejniece, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977708/
https://www.ncbi.nlm.nih.gov/pubmed/31919337
http://dx.doi.org/10.12659/AJCR.919616
_version_ 1783490570224664576
author Balode, Dārta
Belajeva, Ludmila
Ruesseler, Vanessa
Quaas, Alexander
Lejniece, Sandra
author_facet Balode, Dārta
Belajeva, Ludmila
Ruesseler, Vanessa
Quaas, Alexander
Lejniece, Sandra
author_sort Balode, Dārta
collection PubMed
description Patient: Female, 46-year-old Final Diagnosis: Cutaneous T cell pseudolymphoma Symptoms: Enlarged cervical lymph nodes Medication: — Clinical Procedure: — Specialty: Hematology OBJECTIVE: Rare disease BACKGROUND: Pseudolymphoma is a rare disorder that can mimic lymphoma both clinically and histologically. It usually affects middle-aged females. Since pseudolymphoma is a rare disorder not only is diagnosing the condition difficult, but there is also a lack of standardized treatment guidelines. In the literature, anti-CD20 monoclonal antibody rituximab is described as an effective treatment option. CASE REPORT: 46-year-old female fell ill suddenly with swelling and enlargement of her chin. Multiple skin biopsies were done, which were re-evaluated multiple times as well. Each ended with a new diagnosis for the patient. Finally, in the last revision of biopsy material, pseudolymphoma was confirmed. The patient received multiple courses of corticosteroid treatments – locally and systemically – without long lasting effect. After diagnosis of pseudolymphoma, the patient was started on intravenous rituximab and this treatment was effective. CONCLUSIONS: Cutaneous pseudolymphoma is a diagnostic challenge. Rituximab is a treatment option for refractory pseudolymphoma. Since there are no treatment guidelines for pseudolymphoma, more clinical studies are needed to establish best treatment options for these patients. Therefore, each reported clinical case is important.
format Online
Article
Text
id pubmed-6977708
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-69777082020-02-03 Diagnostic Challenges and Treatment Options for Cutaneous T Cell Pseudolymphoma: A Case Study with Rituximab Treatment Balode, Dārta Belajeva, Ludmila Ruesseler, Vanessa Quaas, Alexander Lejniece, Sandra Am J Case Rep Articles Patient: Female, 46-year-old Final Diagnosis: Cutaneous T cell pseudolymphoma Symptoms: Enlarged cervical lymph nodes Medication: — Clinical Procedure: — Specialty: Hematology OBJECTIVE: Rare disease BACKGROUND: Pseudolymphoma is a rare disorder that can mimic lymphoma both clinically and histologically. It usually affects middle-aged females. Since pseudolymphoma is a rare disorder not only is diagnosing the condition difficult, but there is also a lack of standardized treatment guidelines. In the literature, anti-CD20 monoclonal antibody rituximab is described as an effective treatment option. CASE REPORT: 46-year-old female fell ill suddenly with swelling and enlargement of her chin. Multiple skin biopsies were done, which were re-evaluated multiple times as well. Each ended with a new diagnosis for the patient. Finally, in the last revision of biopsy material, pseudolymphoma was confirmed. The patient received multiple courses of corticosteroid treatments – locally and systemically – without long lasting effect. After diagnosis of pseudolymphoma, the patient was started on intravenous rituximab and this treatment was effective. CONCLUSIONS: Cutaneous pseudolymphoma is a diagnostic challenge. Rituximab is a treatment option for refractory pseudolymphoma. Since there are no treatment guidelines for pseudolymphoma, more clinical studies are needed to establish best treatment options for these patients. Therefore, each reported clinical case is important. International Scientific Literature, Inc. 2020-01-10 /pmc/articles/PMC6977708/ /pubmed/31919337 http://dx.doi.org/10.12659/AJCR.919616 Text en © Am J Case Rep, 2020 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Articles
Balode, Dārta
Belajeva, Ludmila
Ruesseler, Vanessa
Quaas, Alexander
Lejniece, Sandra
Diagnostic Challenges and Treatment Options for Cutaneous T Cell Pseudolymphoma: A Case Study with Rituximab Treatment
title Diagnostic Challenges and Treatment Options for Cutaneous T Cell Pseudolymphoma: A Case Study with Rituximab Treatment
title_full Diagnostic Challenges and Treatment Options for Cutaneous T Cell Pseudolymphoma: A Case Study with Rituximab Treatment
title_fullStr Diagnostic Challenges and Treatment Options for Cutaneous T Cell Pseudolymphoma: A Case Study with Rituximab Treatment
title_full_unstemmed Diagnostic Challenges and Treatment Options for Cutaneous T Cell Pseudolymphoma: A Case Study with Rituximab Treatment
title_short Diagnostic Challenges and Treatment Options for Cutaneous T Cell Pseudolymphoma: A Case Study with Rituximab Treatment
title_sort diagnostic challenges and treatment options for cutaneous t cell pseudolymphoma: a case study with rituximab treatment
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977708/
https://www.ncbi.nlm.nih.gov/pubmed/31919337
http://dx.doi.org/10.12659/AJCR.919616
work_keys_str_mv AT balodedarta diagnosticchallengesandtreatmentoptionsforcutaneoustcellpseudolymphomaacasestudywithrituximabtreatment
AT belajevaludmila diagnosticchallengesandtreatmentoptionsforcutaneoustcellpseudolymphomaacasestudywithrituximabtreatment
AT ruesselervanessa diagnosticchallengesandtreatmentoptionsforcutaneoustcellpseudolymphomaacasestudywithrituximabtreatment
AT quaasalexander diagnosticchallengesandtreatmentoptionsforcutaneoustcellpseudolymphomaacasestudywithrituximabtreatment
AT lejniecesandra diagnosticchallengesandtreatmentoptionsforcutaneoustcellpseudolymphomaacasestudywithrituximabtreatment